Status:
RECRUITING
Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
Lead Sponsor:
Yonsei University
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
19-84 years
Phase:
NA
Brief Summary
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after pe...
Detailed Description
Prospective, open label, multicenter randomized clinical trial
Eligibility Criteria
Inclusion
- Over 19 years old
- Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR \<45 / \<30 / \<15 or dialysis)
- Patients treated with a new generation drug eluting stent.
- Patients who signed consent form
Exclusion
- Over 85 years old
- Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke, dementia or central nervous system damage within 1 year 3) Head trauma or brain surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6) Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8) In case of major surgery, trauma or bleeding within 3 weeks
- Patients who need oral anticoagulant
- Pregnant women or women of childbearing age
- Life expectancy is less than 1 year
- Patients with a history of intracranial bleeding
- Moderate to severe hepatic impairment (Child-Pugh class B or C)
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 13 2028
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT04708587
Start Date
March 23 2021
End Date
March 13 2028
Last Update
October 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, South Korea